



2012-09-24

PRESS RELEASE

Communiqué from Annual General Meeting 2012

Oasmia Pharmaceutical AB (publ.) VAT no SE556332-667601 held its Annual General Meeting for the fiscal year 2011/2012 on Friday, September 24, 2012 and the following resolutions were made. For detailed information about the content of the resolutions, see the complete notice for Annual General Meeting available at the Oasmia website www.oasmia.com together with the complete proposals for the resolutions below.

Establishment of Balance Sheet and Income Statement

The Annual General Meeting established the Balance Sheet, Income Statement, Consolidated Accounts and Financial report. It was resolved that share premium reserve SEK 457 831 705, accumulated profit of SEK -129 027 586, and profit for the year SEK -65 823 485, in total SEK 262 980 634, shall be carried forward.

The Board of Directors and auditors

The Annual General Meeting discharged the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2011/2012. The AGM made a resolution that the Board shall consist of six regular members without deputies. The AGM re-elected the Board members Joel Citron, Martin Nicklasson, Jan Lundberg, Horst Domdey, Bo Cederstrand and Julian Aleksov. Joel Citron was elected as Chairman of the Board. Ernst & Young AB, with principal auditor Björn Ohlsson, was elected as auditors.

Remuneration to the Board and auditors

The AGM established that a member of the Board not employed by the company shall receive remuneration amounting to SEK 150 000. The Chairman of the Board shall receive payment of SEK 175 000. Remuneration to a Board member may, by special agreement with Oasmia Pharmaceutical AB, be invoiced by a company wholly-owned by the Board member. In that case, the invoiced fee will be increased by the amount of social security contributions and VAT. Remuneration to the auditors shall be paid according to bill.

Guidelines for remuneration to senior managers

The AGM approved the guidelines for remuneration to senior managers proposed by the Board.

Nomination committee

The AGM approved the proposal concerning criteria for the selection of a nomination committee for the AGM 2013.

The Board's proposal for the authorization of repurchase and transfer the company's own shares

The AGM made a resolution to, in accordance with the proposal by the Board, authorize the Board of Directors to resolve to repurchase, on one or several occasions prior to the next annual general meeting, as many shares as may be purchased without the company's holding at any time does not exceed 10 per cent of the total number of shares in the company. The shares shall be purchased on NASDAQ OMX Stockholm and only at a price within the price range registered at any given time, i.e. the range between the highest bid price and the lowest offer price.

The Board of Directors shall also be authorized to resolve, on one or several occasions during the period until the next annual general meeting, to transfer all shares held by the company, via NASDAQ OMX Stockholm or in connection with the acquisition of companies, businesses or parts thereof on market terms, however, not to a price lower than current stock market value. Transfer of shares on the NASDAQ OMX Stockholm may at a price within the price range registered at any given time, i.e. the range between the highest bid price and the lowest offer price.

Authorization for the Board to make decisions on issue of new shares and convertible debt instruments

The AGM made a resolution to, in accordance with the proposal by the Board, authorize the Board to make, at one or more occasions, with or without deviation from shareholders' preferential rights, new share issues for cash payment and/or in kind or offset, or otherwise in accordance with cpt 13 § 7 of the Companies Act, and new issues of convertibles for cash payment and/or in kind or offset, or otherwise in accordance with cpt 15 § 5 of the Companies Act. The total number of shares issued supported by the authorization may not exceed 25 000 000. The total number of convertibles issued supported by the authorization may not exceed more convertibles than enables conversion to 25 000 000 shares.

For more information, please contact: Johan Edin, acting Head of Public Relations, Oasmia Pharmaceutical AB.
E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also available at www.oasmia.com
www.nasdaqomxnordic.com www.boerse-frankfurt.de

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 16.00 CET on September 24, 2012."